Phase 2 pilot study evaluates ticagrelor monotherapy safety after stenting for acute MI Can a single blood thinner prevent heart attacks after stent placement?

A single-center, single-arm, prospective phase II pilot study of 200 patients assessed the initial safety of ticagrelor monotherapy after coronary stenting for NSTEMI or STEMI. The primary endpoint was the composite of cardiac death, spontaneous myocardial infarction, or definite/probable stent thrombosis within 3 months.

Doctors are testing whether ticagrelor alone is safe enough to prevent dangerous heart complications after a stent is placed for a heart attack. This pilot study is tracking 200 patients for three months to see if this simpler medication approach works. The results could mean fewer medications for people recovering from a serious heart event.